Role of Continuous Theta Burst Stimulation as Potential Biomarker of Levodopa-induced Dyskinesias in Patients With Parkinson's Disease.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson Disease
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Alterations of synaptic depotentiation in primary motor cortex
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The primary endpoint of the study is to identify a neurophysiological biomarker (absence of synaptic depotentiation at primary motor cortex , measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of neurophysiological cTBS depotentiation protocol) as predictor of the development of Levodopa-induced dyskinesia in patients with Parkinson's disease.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with diagnosis of idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria;
- •age between 30 and 80 years;
- •ongoing therapy with levodopa;
- •fulfillment of requirements for the application of transcranial magnetic stimulation (TMS), assessed by completion of the TMS screening questionnaire.
Exclusion Criteria
- •patients unable to give informed consent;
- •cognitive impairment (MMSE ≤ 24);
- •history of epilepsy;
- •pregnant women.
Outcomes
Primary Outcomes
Alterations of synaptic depotentiation in primary motor cortex
Time Frame: 3 years
Alterations of synaptic depotentiation in primary motor cortex will be measured as change in the amplitude of motor evoked potentials recorded at the dorsal first interosseus muscle after administration of depotentiation protocol of continuous theta burst stimulation. Alterations of synaptic depotentiation at the baseline evaluation will be compared between patients who will develop and patients who will not develop dyskinesias (assessed by Unified Dyskinesia Rating Scale part III, range 0-112) during the follow-up.